Shire plc, a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in Ireland (IE) and operates extensively across Europe, North America, and Asia. Founded in 1986, Shire has established itself as a leader in developing innovative therapies for rare diseases and complex conditions, focusing on areas such as neuroscience, immunology, and genetic disorders.
The company is renowned for its unique portfolio of products, including treatments for attention deficit hyperactivity disorder (ADHD) and rare genetic disorders, which set it apart in a competitive market. Shire's commitment to research and development has led to significant milestones, including numerous FDA approvals and a strong market position, making it a trusted name in the pharmaceutical sector. With a dedication to improving patient outcomes, Shire continues to advance its mission of transforming the lives of those with challenging health conditions.
+16 vs industry average
Shire plc’s score of 54 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Shire plc?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
Scope 3 accounts for ••• of total emissions.
Shire plc's reported carbon emissions
As a pharmaceutical preparation manufacturing company headquartered in IE, Shire plc's most recent disclosed emissions data is for 2016. In that year, the company reported total greenhouse gas emissions of approximately 83,119,000 kg CO2e. This total comprised Scope 1 emissions of about 26,234,000 kg CO2e, Scope 2 emissions of approximately 118,000,000 kg CO2e, and Scope 3 emissions of around 34,078,000 kg CO2e. Scope 1 and 2 emissions combined were approximately 49,041,000 kg CO2e. Shire plc's climate commitments are primarily cascaded from its ultimate parent company. Emissions data for Shire plc is inherited from its parent, Takeda Pharmaceutical Company Limited. Specifically, Science Based Targets initiative (SBTi) reduction targets are cascaded from Takeda Pharmaceutical Company Limited, indicating a corporate-wide approach to climate action. While specific reduction targets for Shire plc are not detailed in the provided information, the SBTi alignment suggests a commitment to emissions reductions in line with climate science. Further details on climate initiatives for Shire plc, such as RE100 or Climate Pledge commitments, are not explicitly disclosed for this specific entity.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Shire plc’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Shire plc yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Takeda Pharmaceutical Company Limited
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Takeda Pharmaceutical Company Limited
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Shire plc
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project